0.25mg Semaglutide: What the Starting Dose Actually Does

Why the licensed schedule opens at 0.25mg

The Wegovy prescribing programme was designed around a staged titration for a practical reason: the side effects most people experience on semaglutide are gastrointestinal (nausea, loose stools, occasional vomiting) and they are most pronounced when the medicine is new to the body or when the dose rises. Starting at 0.25mg gives the gut roughly four weeks to adapt before the dose moves to 0.5mg. This is written into the licensed prescribing information and reflects what the clinical trials actually used.

The STEP 1 trial, whose results appeared in the New England Journal of Medicine, followed this exact titration pathway. Participants began on 0.25mg and moved upward approximately every four weeks, reaching the 2.4mg maintenance dose where the 15% average weight-loss figure was recorded at 68 weeks. The 0.25mg period contributed nothing measurable to that outcome figure on its own, its job was to make the rest of the schedule tolerable enough to stay on.

A question our prescribers hear most weeks is whether it is safe to skip the starter dose and begin higher. The answer from the licensed guidance is no: the titration exists because rushing the schedule increases the chance of severe nausea or vomiting that causes people to stop treatment altogether. Reaching the maintenance dose slowly produces better long-term outcomes than pushing through side effects that could cut the journey short.

How 0.25mg semaglutide fits into the full titration ladder

The licensed UK titration schedule for Wegovy runs from 0.25mg through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg as the standard maintenance dose. With the MHRA's approval of a higher 7.2mg dose in early 2026, the ladder can now extend further, though that step is guided entirely by the prescriber and is not appropriate for everyone. You can find detail on the 1mg semaglutide stage or look ahead to the 1.25mg dose context if those are the stages relevant to where you currently are.

Each rung of the schedule is separated by roughly four weeks. Prescribers do sometimes keep patients at an earlier dose for longer if side effects have been significant; moving up before tolerating the current dose well is not clinically recommended. The NHS semaglutide medicines page describes the general titration approach and what to do if doses are missed, always the right first reference point alongside your own Patient Information Leaflet.

What the 0.25mg phase often does produce, even without measurable clinical weight loss, is an early reduction in appetite. Some people notice this within the first week or two. That effect tends to build as the dose rises, which is one reason the titration schedule is worth following rather than treating the first month as a waiting period to get through.

Practical points for the 0.25mg injection period

Semaglutide is injected once weekly, subcutaneously, into the abdomen, thigh or upper arm, rotating the site each time. The pen is stored refrigerated; once in use it has a limited period at room temperature, detailed in the Patient Information Leaflet, follow that, not a general rule. If you are using a pre-filled pen for the first time, the 0.25mg syringe and injection guidance page covers technique questions that are worth reading before your first dose.

Side effects at 0.25mg are generally milder than at higher doses because the pharmacological effect is lower, but nausea and mild digestive discomfort are still common in the first days. Eating smaller portions and avoiding rich or fatty meals during the first week or two helps most people. These effects are not a sign anything has gone wrong; they are the body responding to a new medicine.

Wegovy is licensed for weight management alongside a reduced-calorie diet and increased physical activity, the injection is one part of a broader approach, not a standalone fix. The weight loss treatment overview covers how these elements fit together. On the cost side, the Wegovy price page sets out what private treatment typically involves financially, which is worth reading before starting.

Who the 0.25mg starting dose applies to

The licensed eligibility criteria for semaglutide for weight management in the UK cover adults with a BMI of 30 or above, or a BMI from 27 upward alongside at least one weight-related health condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. Every person who reaches the 0.25mg starting dose has first been assessed as suitable for the medicine by a prescriber; the dose itself is not the point at which eligibility is decided.

Semaglutide is not licensed for people who are pregnant, breastfeeding or trying to conceive. It is not licensed for under-18s either. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use it. These exclusions are assessed at consultation, before any prescription is written. The 0.25mg Wegovy page goes into the pen-specific detail around this starting dose.

If you are considering semaglutide and want to understand whether it is clinically appropriate for your situation, the right step is a consultation with a qualified prescriber rather than a reading of dose schedules alone. Our clinical team at nume reviews every consultation personally. When you are ready, start your free consultation and a GPhC-registered prescriber will assess your suitability the same day.